Teijin Pharma has signed a joint research agreement with Aska Pharmaceutical to accelerate the development of new small molecule drugs for gynecological diseases[1][2]. The collaboration combines Teijin's expertise in computer-aided drug design (CADD) and artificial intelligence with Aska's clinical experience in gynecological diseases[1][2]. Both companies will focus on identifying the so-called "hit" compounds that interact with specific molecular targets, and will subsequently optimize them to achieve the desired efficacy, pharmacokinetic properties and safety[1][2]. Teijin Pharma has improved its drug discovery platform using accurate simulations and predictive models, reducing development times and increasing the likelihood of success[2]. Aska Pharmaceutical is a specialty company with extensive experience in obstetrics and gynecology and has a product portfolio targeting unmet medical needs in women's health care[1][2]. The goal of the partnership is to provide innovative treatments that will improve the quality of life of women with gynecological diseases[2].